Novartis Is Confident In Prexige’s Prospects Despite Arcoxia AC Debacle
Executive Summary
Novartis is confident its COX-2 inhibitor Prexige does not raise the same safety concerns cited by an FDA advisory committee in recommending against approval of Merck's COX-2 agent Arcoxia